The news of PS-5382 didnt seem bad to me. The difficulty Pharmaxis have had in driving PXS-5382 into Phase 2/3 trials ( and needing to attract big pharma company money to do this) was the very public failure of the Gilead molecule which works in a similar way. The new reported study seems to indicate that PXS-5382 works in a different way.
My guess is the studies were run with the specific aim of of showing prospective partners that PXS-5382 works in a different way and may be worth looking at again.
PXS Price at posting:
10.0¢ Sentiment: Hold Disclosure: Held
